Medytox Solutions (MMMS) 10-Q 19 Nov 14 2014 Q3 Quarterly report Financial data

Document_and_Entity_Informatio

Document and Entity Information	9 Months Ended
	Sep. 30, 2014	Nov. 17, 2014
Document And Entity Information	'	'
Entity Registrant Name	'Medytox Solutions, Inc.	'
Entity Central Index Key	'0001374536	'
Document Type	'10-Q	'
Document Period End Date	30-Sep-14	'
Amendment Flag	'false	'
Current Fiscal Year End Date	'--12-31	'
Is Entity a Well-known Seasoned Issuer?	'No	'
Is Entity a Voluntary Filer?	'No	'
Is Entity's Reporting Status Current?	'Yes	'
Entity Filer Category	'Smaller Reporting Company	'
Entity Common Stock, Shares Outstanding	'	29,039,836
Document Fiscal Period Focus	'Q3	'
Document Fiscal Year Focus	'2014	'

Consolidated_Balance_Sheets

Consolidated Balance Sheets (USD $)	Sep. 30, 2014	Dec. 31, 2013
Current assets:	'	'
Cash	$1,763,728	$4,141,416
Accounts receivable, net	21,375,024	10,986,368
Prepaid expenses and other current assets	334,108	194,137
Deferred tax assets	686,700	1,748,600
Assets attributable to disputed activity	0	1,367,796
Total current assets	24,159,560	18,438,317
Property and equipment, net	5,328,297	2,156,381
Other assets:	'	'
Intangible assets	3,190,613	3,190,613
Goodwill	5,317,347	1,425,999
Deposits	173,278	96,747
Total assets	38,169,095	25,308,057
Current liabilities:	'	'
Accounts payable	2,301,101	1,755,965
Accrued expenses	3,365,644	2,855,884
Income tax liabilities	9,557,545	6,052,740
Disputed net income - Trident	0	397,918
Current portion of notes payable	800,000	3,689,554
Current portion of capital lease obligations	727,601	193,095
Liabilities attributable to disputed activity	0	1,104,063
Total current liabilities	16,751,891	16,049,219
Other liabilities:	'	'
Notes payable, net of current portion	100,000	42,107
Capital lease obligations, net of current portion	1,617,727	405,718
Deferred tax liabilities	42,000	41,800
Total liabilities	18,511,618	16,538,844
Commitments and contingencies	'	'
Stockholders' equity:	'	'
Common stock, $0.0001 par value, 500,000,000 shares authorized, 29,039,386 and 29,996,386 shares issued and outstanding at September 30, 2014 and December 31, 2013, respectively	2,904	3,000
Additional paid-in-capital	5,062,539	1,905,223
Deferred issuance costs	0	-12,500
Retained earnings	14,470,999	6,752,485
Total Medytox Solutions stockholders' equity	19,536,473	8,648,209
Noncontrolling interest	121,004	121,004
Total stockholders' equity	19,657,477	8,769,213
Total liabilities and stockholders' equity	38,169,095	25,308,057
Series B Preferred Stock	'	'
Stockholders' equity:	'	'
Preferred stock, 100,000,000 shares authorized:	1	1
Series C Preferred Stock	'	'
Stockholders' equity:	'	'
Preferred stock, 100,000,000 shares authorized:	0	0
Series D preferred stock	'	'
Stockholders' equity:	'	'
Preferred stock, 100,000,000 shares authorized:	20	0
Series E Preferred Stock [Member]	'	'
Stockholders' equity:	'	'
Preferred stock, 100,000,000 shares authorized:	$10	$0

Consolidated_Balance_Sheets_Pa

Consolidated Balance Sheets (Parenthetical) (USD $)	Sep. 30, 2014	Dec. 31, 2013
Preferred stock shares authorized	100,000,000	100,000,000
Common stock par value	$0.00	$0.00
Common stock shares authorized	500,000,000	500,000,000
Common stock shares issued	29,039,386	29,996,386
Common stock shares outstanding	29,036,386	29,996,386
Series B Preferred Stock	'	'
Preferred stock shares authorized	5,000	5,000
Preferred stock par value	$0.00	$0.00
Preferred stock shares issued	5,000	5,000
Preferred stock shares outstanding	5,000	5,000
Series C Preferred Stock	'	'
Preferred stock shares authorized	1,000,000	1,000,000
Preferred stock par value	$0.00	$0.00
Preferred stock shares issued	0	0
Preferred stock shares outstanding	0	0
Series D preferred stock	'	'
Preferred stock shares authorized	200,000	200,000
Preferred stock par value	$0.00	$0.00
Preferred stock shares issued	200,000	0
Preferred stock shares outstanding	200,000	0
Series E Preferred Stock [Member]	'	'
Preferred stock shares authorized	100,000	100,000
Preferred stock par value	$0.00	$0.00
Preferred stock shares issued	100,000	0
Preferred stock shares outstanding	100,000	0

Consolidated_Statements_of_Ope

Consolidated Statements of Operations (USD $)	3 Months Ended		9 Months Ended
	Sep. 30, 2014	Sep. 30, 2013	Sep. 30, 2014	Sep. 30, 2013
Income Statement [Abstract]	'	'	'	'
Gross charges (net of contractual allowances and discounts)	$22,829,064	$16,729,526	$64,676,062	$33,355,862
Provision for bad debts	-4,613,097	-3,717,376	-15,630,857	-7,794,361
Net Revenues	18,215,967	13,012,150	49,045,205	25,561,501
Operating expenses:	'	'	'	'
Direct costs of revenue	4,136,520	3,291,530	11,601,402	6,987,777
General and administrative	5,898,715	4,529,506	14,075,030	9,171,359
Legal fees related to disputed subsidiary	0	267,286	94,217	857,587
Sales and marketing expenses	1,472,298	691,159	3,507,582	1,923,843
Depreciation and amortization	404,557	118,998	800,727	323,031
Total operating expenses	11,912,090	8,898,479	30,078,958	19,263,597
Income from operations	6,303,877	4,113,671	18,966,247	6,297,904
Other income (expense):	'	'	'	'
Other income	152	64	405	273
Gain on settlement of assets	0	400	0	750
Gain on disposition of subsidiary	0	0	134,185	0
Loss on legal settlement	0	-100,000	0	-169,800
Interest expense	-118,603	-68,785	-316,299	-332,387
Total other income (expense)	-118,451	-168,321	-181,709	-501,164
Income before income taxes	6,185,426	3,945,350	18,784,538	5,796,740
Provision for income taxes	2,454,205	1,141,000	7,250,305	1,655,900
Net income attributable to Medytox Solutions	3,731,221	2,804,350	11,534,233	4,140,840
Preferred stock dividends	1,391,614	913,132	3,815,719	1,396,238
Net income attributable to Medytox Solutions common shareholders	$2,339,607	$1,891,218	$7,718,514	$2,744,602
Net income per common share: Basic	$0.08	$0.06	$0.26	$0.09
Net income per common share: Diluted	$0.08	$0.06	$0.25	$0.09
Weighted average number of shares outstanding during the period - Basic	30,281,386	29,692,110	30,186,893	29,610,287
Weighted average number of shares outstanding during the period - Diluted	30,741,651	30,217,565	30,565,526	30,059,226

Consolidated_Statements_of_Cas

Consolidated Statements of Cash Flows (USD $)	9 Months Ended
	Sep. 30, 2014	Sep. 30, 2013
Cash flows from operating activities:	'	'
Net income	$11,534,233	$4,140,840
Adjustments to reconcile net income to net cash provided by operations:	'	'
Depreciation and amortization	800,727	323,031
Stock issued in lieu of cash compensation	162,500	0
Stock issued for services	0	62,500
Stock-based compensation	394,750	452,500
Stock-based consulting fees	0	85,000
Bad debts	15,630,857	7,794,361
Accretion of loan costs as interest	0	155,342
Accretion of beneficial conversion feature as interest	3,278	34,532
Write-off of deferred issuance costs	12,500	0
Gain on disposition of subsidiary	-134,185	0
Gain on disposal of equipment	0	-750
Changes in operating assets and liabilities:	'	'
Accounts receivable	-25,792,226	-11,647,148
Prepaid expenses and other current assets	-139,730	-25,078
Deferred tax assets	1,061,900	787,500
Security deposits	-75,831	-131,213
Accounts payable	185,108	704,636
Accrued expenses	791,541	1,497,823
Income tax liabilities	3,504,805	789,200
Deferred tax liabilities	200	79,200
Net cash provided by operating activities	7,940,427	5,102,276
Cash flows provided by (used in) investing activities:	'	'
Purchase of property and equipment	-1,417,979	-862,645
Cash received in sale of property and equipment	0	750
Cash paid for acquisitions	-1,600,000	-735,052
Cash received in acquisitions	31,671	3,735
Net cash used in investing activities	-2,986,308	-1,593,212
Cash flows provided by (used in) financing activities:	'	'
Proceeds from the sale of common stock	0	116,000
Deferred issuance costs	0	-103,949
Dividends on Series B preferred stock	-3,815,719	-1,396,238
Proceeds from issuance of notes payable	0	1,300,000
Payments on notes payable	-3,234,939	-2,278,910
Payments on capital lease obligations	-281,149	-86,705
Payments on related party loans	0	-195,000
Common stock repurchased from lender	0	-100,000
Net cash used in financing activities	-7,331,807	-2,744,802
Net increase (decrease) in cash	-2,377,688	764,262
Cash at beginning of period	4,141,416	1,773,785
Cash at end of period	1,763,728	2,538,047
Supplemental disclosure of cash flow information:	'	'
Cash paid for interest	258,087	257,963
Cash paid for taxes	2,720,498	0
Non-cash investing and financing activities:	'	'
Net liabilities acquired in acquisitions, net of cash	1,212,331	1,565,613
Goodwill	-3,891,348	-2,640,613
Contingent acquisition liability	54,017	0
Acquisition payment liabilities	150,000	0
Notes payable issued	400,000	1,075,000
Common stock	1	0
Series D preferred stock	20	0
Series E preferred stock	10	0
Additional paid in capital	2,074,969	0
Property and equipment acquired with issuance of notes payable	0	-56,603
Notes payable issued	0	56,603
Common stock issued as payment of accrued bonuses:	'	'
Accrued bonuses	-525,000	0
Common stock	21	0
Additional paid in capital	524,979	0
Capital lease assets acquired	-2,027,664	0
Capital lease obligations	2,027,664	0
1,241,550 common shares returned and cancelled from Officer and Director:	'	'
Common stock	-124	0
Additional paid in capital	124	0
Related party loans forgiven:	'	'
Loans and notes payable, related parties	0	-47,100
Additional paid in capital	0	47,100
Beneficial conversion feature of convertible notes payable:	'	'
Notes payable	0	-55,558
Additional paid in capital	0	55,558
Adjustment to purchase price for Biohealth Medical Laboratory, Inc.:	'	'
Goodwill	0	29,024
Notes payable issued	0	-24,678
Accrued expenses	0	-4,346
Adjustment to purchase price for Medical Billing Choices, Inc.:	'	'
Goodwill	0	-400,000
Common stock	0	16
Additional paid in capital	$0	$399,984

1_Organization_and_Presentatio

1. Organization and Presentation	9 Months Ended
	Sep. 30, 2014
Organization, Consolidation and Presentation of Financial Statements [Abstract]	'
1. Organization and Presentation	'
	Organization
	Medytox Solutions, Inc. (the “Company”) was incorporated in Nevada on July 20, 2005 as Casino Players, Inc. In the first half of 2011, Company management decided to reorganize the operations of the Company as a holding company to acquire and manage a number of companies in the medical services sector.
	On March 18, 2014, the Company's wholly-owned subsidiary, Medytox Information Technology, Inc. (“MIT”), purchased 100% of the stock of Clinlab, Inc. ("Clinlab"). Clinlab develops and markets laboratory information management systems.
	On May 9, 2014, the Company formed Medical Mime, Inc. (“Mime”), a Florida corporation, as a wholly-owned subsidiary.
	On May 23, 2014, Mime purchased certain net assets, primarily consisting of software, of GlobalOne Information Technologies, LLC (“GlobalOne”). GlobalOne developed software and provided services for the Electronic Health Records (“EHR”) segment of the medical industry.
	On August 26, 2014, the Company's wholly-owned subsidiary, Medytox Diagnostics, Inc. (“MDI”), purchased 100% of the stock of Epinex Diagnostics Laboratories, Inc. ("Epinex"), a clinical laboratory in Tustin, California.
	Basis of Presentation
	The accompanying unaudited interim condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States (“U.S. GAAP”) for interim financial statement presentation and in accordance with Form 10-Q. Accordingly, they do not include all of the information and footnotes required in annual financial statements. In the opinion of management, the unaudited interim condensed consolidated financial statements contain all adjustments (consisting only of normal recurring accruals) necessary to present fairly the financial position and results of operations and cash flows for the interim periods reported in this Form 10-Q. The results of operations presented are not necessarily indicative of the results to be expected for any other interim period or for the entire year.
	These unaudited interim condensed consolidated financial statements should be read in conjunction with the 2013 audited annual financial statements included in the Annual Report on Form 10-K, filed with the U.S. Securities and Exchange Commission (“SEC”) on March 31, 2014.
	The historical accounting for the Company’s Series B Preferred shares is currently being evaluated. (See Note 7). Management believes that the unaudited condensed financial statements herein and those previously reported are fairly stated in all material respects.
	The independent accountants have not completed their review of the current quarter’s financial statements herein.
	Contractual Allowances and Doubtful Accounts
	Accounts receivable are presented net of allowances for uncollectible amounts of $12,262,894 and $3,621,814 at September 30, 2014 and December 31, 2013, respectively.
	Reclassifications
	The provision for bad debts has been classified on the statements of operations as a reduction of revenues for all periods presented herein. Certain other items on the statements of operations for the three and nine months ended September 30, 2013 and the statement of cash flows for the nine months ended September 30, 2013 have been reclassified to conform to current period presentation.

2_Disputed_Subsidiary

2. Disputed Subsidiary	9 Months Ended
	Sep. 30, 2014
Organization, Consolidation and Presentation of Financial Statements [Abstract]	'
2. Disputed Subsidiary	'
	On July 2, 2013, a jury awarded our wholly-owned subsidiary, Medytox Institute of Laboratory Medicine, Inc. ("MILM"), $2,906,844 on its breach of contract claim against Trident Laboratories, Inc. ("Trident"), and Trident's shareholders, Michele Steegstra, Christopher Hawley, Donette Hawley, Michael Falestta and Skyler Lukas ("Shareholders"), and awarded Seamus Lagan $750,000 individually against Christopher Hawley for Mr. Hawley's defamatory postings on the internet. The jury rejected every claim made against the MILM parties. All appeals have been dismissed.
	The case arose from the August 22, 2011 agreement among MILM and Trident and its Shareholders pursuant to which MILM was to acquire 81% of Trident. On January 17, 2012, Trident notified MILM that it was rescinding the agreement. As a result, MILM filed suit against Trident and its Shareholders in Florida Circuit Court in Broward County. The jury found that Trident and its Shareholders breached the agreement and failed to perform their obligations thereunder.
	Legal fees related to the lawsuit were $-0- and $267,286 for the three months ended September 30, 2014 and 2013, respectively, and $94,217 and $857,587 for the nine months ended September 30, 2014 and 2013, respectively.
	The Company has not received any financial statements of Trident since August 31, 2012. The consolidated financial statements of the Company were prepared without the financial information relating to Trident.  Management believes that the financial information relating to Trident is immaterial to the consolidated financial statements as a whole. The Company had established a disputed net income reserve of $397,918 as of December 31, 2013, representing all of Trident's net income recognized by the Company since August 22, 2011, the date of acquisition. The assets and liabilities of Trident had been condensed and presented as assets, or liabilities, attributable to disputed activity in the December 31, 2013 consolidated balance sheet. A separate $389,135 of commissions payable on Trident sales was included in liabilities attributable to disputed activity as of December 31, 2013. Effective March 31, 2014, the Company’s management believed that the net assets of Trident are not recoverable and, as such, the Company has accounted for the disputed assets and liabilities as if they have been disposed, resulting in a gain on the disposition of $134,185.
	Assets and liabilities of the disputed subsidiary as of September 30, 2014 and December 31, 2013 were as follows:
		September 30,		December 31,
		2014		2013
	Total assets	$	-0-	$	1,367,796
	Total liabilities	$	-0-	$	1,104,063

3_LongLived_Assets

3. Long-Lived Assets	9 Months Ended
	Sep. 30, 2014
Property, Plant and Equipment [Abstract]	'
3. Long-Lived Assets	'
	Property and equipment at September 30, 2014 and December 31, 2013 consisted of the following:
		September 30,			December 31,
		2014			2013
	Medical equipment	$	824,328		$	655,125
	Equipment		256,918			111,265
	Equipment under capital leases (See Note 6 - Capital Lease Obligations)		3,008,613			980,948
	Furniture		234,199			206,587
	Leasehold improvements		886,860			243,983
	Vehicles		292,509			177,534
	Computer equipment		475,161			235,507
	Software		890,179			285,175
			6,868,767			2,896,124
	Less accumulated depreciation		(1,540,470	)		(739,743	)
	Property and equipment, net	$	5,328,297		$	2,156,381
	Depreciation of property and equipment was $800,727 and $323,031 for the nine months ended September 30, 2014 and 2013, respectively.
	Management has retained a third party valuation firm to assist in the valuation the identifiable intangible assets acquired and the equity portion of the consideration given to the seller.  Until the valuation is complete and final values are assigned to the identifiable intangible assets acquired, the entire amount of the excess of the estimated consideration given over the working capital acquired, has been provisionally allocated to goodwill. See Note 9 – Business Combinations.
	Management periodically reviews the valuation of long-lived assets for potential impairments. Management has not recognized an impairment of these assets to date, and does not anticipate any negative impact from known current business developments. The Company anticipates completing the annual impairment analysis in early December.

4_Notes_Payable

4. Notes Payable	9 Months Ended
	Sep. 30, 2014
Debt Disclosure [Abstract]	'
4. Notes Payable	'
	The Company and its subsidiaries are party to a number of loans with affiliates and unrelated parties. At September 30, 2014 and December 31, 2013, notes payable consisted of the following:
		September 30,			December 31,
		2014			2013
	Convertible debenture for working capital, dated September 15, 2011, in the amount of $500,000 and bearing interest at 20%. The note was convertible at $2.50 per share. The due date of the note was extended from October 31, 2013 to February 5, 2014 by the lender. The note was paid in full on February 5, 2014.	$	–		$	100,000
	Loan from TCA. Principal of $2,475,000 and $2,475,000, respectively, payable by January 15, 2014.  The note was extended from January 15, 2014 to September 15, 2014 and was secured by all assets of the Company and its subsidiaries (other than Trident and MBC). See "TCA Global" below.		–			2,475,000
	Acquisition note No.1 to former shareholder of Alethea Laboratories, Inc. in the amount of $287,500 at 0% interest, with payments of $50,000 due quarterly starting April 1, 2013.		–			150,000
	Acquisition note No. 2 to former shareholder of Alethea Laboratories, Inc. in the amount of $287,500 at 0% interest, with payments of $50,000 due quarterly starting April 1, 2013.		–			150,000
	Loan from former shareholders of Alethea Laboratories, Inc. in the amount of $344,650 at 4% interest, with principal payments of $24,618 due monthly starting March 15, 2013. The note was paid in full on April 1, 2014.		–			98,471
	Commercial loan with a finance company, dated December 20, 2012, in the original amount of $18,249 and bearing interest at 12.59%. Principal and interest payments in the amount of $364 were payable for 72 months ending on January 3, 2019. This note was secured by a lien on a vehicle with a carrying value of $16,623 at December 31, 2013. The note was paid in full on March 26, 2014.		–			15,845
	Commercial loan with a finance company, dated November 15, 2012, in the original amount of $18,008 and bearing interest at 15.07%. Principal and interest payments in the amount of $384 are payable for 72 months ending on November 30, 2018. This note was secured by a lien on a vehicle with a carrying value of $16,430 at December 31, 2013. The note was paid in full on March 26, 2014.		–			16,279
	Commercial loan with a finance company, dated November 28, 2012, in the original amount of $20,345 and bearing interest at 8.99%.  Principal and interest payments in the amount of $368 are payable for 72 months ending on January 12, 2019. This note was secured by a lien on a vehicle with a carrying value of $18,300 at December 31, 2013.  The note was paid in full on March 26, 2014.		–			17,676
	Acquisition convertible note No. 1 to former member of International Technologies, LLC in the amount of $250,000 at 5% interest and was due January 17, 2014.  The note was convertible into the Company's common stock at a ten percent (10%) discount to the average market price for the thirty days prior to conversion.  The note is discounted for its unamortized beneficial conversion feature of $-0- and $1,639 at September 30, 2014 and December 31, 2013, respectively.  See "Acquisition Convertible Notes" below.		250,000			248,361
	Acquisition convertible note No. 2 to former member of International Technologies, LLC in the amount of $250,000 at 5% interest and was due January 17, 2014.  The note was convertible into the Company's common stock at a ten percent (10%) discount to the average market price for the thirty days prior to conversion. The note is discounted for its unamortized beneficial conversion feature of $-0- and $1,639 at September 30, 2014 and December 31, 2013, respectively.   See "Acquisition Convertible Notes" below.		250,000			248,361
	Loan from former member of International Technologies, LLC in the remaining amount of $416,667 at the date of acquisition, at 1% interest, with principal payments of $83,333 due quarterly starting June 7, 2013.  The note was paid in full on June 6, 2014.		–			166,668
	Loan from former member of International Technologies, LLC in the remaining amount of $112,500 at the date of acquisition, at 1% interest, with principal payments of $22,500 due quarterly starting June 7, 2013.  The note was paid in full on June 6, 2014.		–			45,000
	Loan payable to former shareholder of Epinex Diagnostic Laboratories, Inc. in the amount of $400,000, at 0% interest, with principal payments of $100,000 due in periodic installments from November 26, 2014 through February 26, 2016.		400,000			–
			900,000			3,731,661
	Less current portion		(800,000	)		(3,689,554	)
	Notes payable, net of current portion	$	100,000		$	42,107
	TCA Global
	Under terms of the Senior Secured Revolving Credit Facility agreement with TCA Global Credit Master Fund, LP, originally signed May 12, 2012 and as subsequently amended, the Company executed an Amended and Restated Revolving Promissory Note, due January 15, 2014, in the amount of $3,025,000. The note was extended by the lender from January 15, 2014 to September 15, 2014. The borrowings under this facility were repaid in full on September 8, 2014.
	Acquisition Convertible Notes
	The Company has filed an action against Reginald Samuels and Ralph Perricelli seeking, among other things, a declaration that the convertible debentures in the aggregate amount of $500,000 that the Company issued to Mr. Samuels and Mr. Perricelli as part of the consideration for the purchase of their interests in International Technologies, LLC are null and void. Mr. Samuels and Mr. Perricelli have been served and the litigation is ongoing.

5_Related_Party_Transactions

5. Related Party Transactions	9 Months Ended
	Sep. 30, 2014
Related Party Transactions [Abstract]	'
5. Related Party Transactions	'
	On September 11, 2014, William Forhan resigned as Chief Executive Officer and Chairman and returned 1,241,550 restricted common shares to the Company, which were then retired. Mr. Forhan remains the owner of 1,241,551 restricted common shares.
	Mr. Forhan was employed as the Company’s Chief Executive Officer pursuant to the terms of an employment agreement dated June 1, 2011, as amended as of September 1, 2013. In connection with his voluntary resignation he entered into an agreement, to be effective as of the date of appointment of a new Chief Executive Officer of the Company, pursuant to which he will receive a severance of $500,000, payable in two installments, the first of $200,000 was paid prior to the effective date of resignation, and the balance to be paid no later than August 31, 2016. In addition, the Agreement provided that Mr. Forhan could participate in any executive bonus plan adopted for calendar year 2014. Mr. Forhan also agreed under the Agreement that any Company stock options previously issued to him, would remain outstanding, subject to their terms, for no longer than 24 months such that the options will expire no later than August 31, 2016. In addition, the Agreement provided, among other things, for the return and cancellation of 1,241,550 shares of Common Stock owned by Mr. Forhan; for the release by Mr. Forhan of any and all claims he may have had against the Company and/or its affiliates; and for Mr. Forhan to abide by certain restrictive covenants, including using his best efforts to protect and maintain the Company's confidential information.

6_Capital_Lease_Obligations

6. Capital Lease Obligations	9 Months Ended
	Sep. 30, 2014
Debt Disclosure [Abstract]	'
6. Capital Lease Obligations	'
	The Company leases various assets under capital leases expiring through 2020 as follows:
		September 30,			December 31,
		2014			2013
	Medical equipment	$	3,008,613		$	980,948
	Less accumulated depreciation		(689,135	)		(364,726	)
	Net	$	2,319,478		$	616,222
	Depreciation expense on assets under capital leases was $324,409 and $98,340 for the nine months ended September 30, 2014 and 2013, respectively.
	Aggregate future minimum rentals under capital leases are as follows:
	Future minimum rentals
	December 31,
	2014	$	227,810
	2015		911,238
	2016		771,302
	2017		662,897
	2018		75,667
	Thereafter		68,186
	Total		2,717,100
	Less interest		371,772
	Present value of minimum lease payments		2,345,328
	Less current portion of capital lease obligations		727,601
	Capital lease obligations, net of current portion	$	1,617,727

7_Stockholders_Equity

7. Stockholders' Equity	9 Months Ended
	Sep. 30, 2014
Equity [Abstract]	'
7. Stockholders' Equity	'
	Authorized Capital
	The Company has 500,000,000 authorized shares of Common Stock at $0.0001 par value per share and 100,000,000 authorized shares of Preferred Stock at $0.0001 par value per share.
	On October 1, 2012, the Company filed a certificate of designation with the Secretary of State of Nevada to designate 5,000 shares of Series B Non-convertible Preferred Stock, at $0.0001 par value per share.  The Series B shares do not include any voting rights and allow for monthly dividends in an amount equal to the sum of 1) 10% of the amount of gross sales in excess of $1 million collected in the ordinary course of business, not to exceed $150,000, and 2) 15% of the amount of gross sales in excess of $2.5 million collected in the ordinary course of business. At each of September 30, 2014 and December 31, 2013, there were 5,000 shares of Series B Preferred Stock outstanding.
	On March 27, 2014, each of the holders of shares of Series B Preferred Stock entered into a purchase option agreement with the Company. Each agreement grants the Company an option to purchase any or all shares of Series B Preferred Stock held by the holder at any time through March 27, 2016 at a purchase price of $5,000 per share. Each holder agreed not to transfer or dispose of any shares of Series B Preferred Stock during the term of the option, other than to the Company upon an exercise of the option. Any exercise of an option is completely at the Company's discretion.
	The Series B Preferred shares (“shares”) contained provisions which allowed the Company, at its sole option, to buy back the shares of a holder in the event the holder terminates employment with the Company. (This option expired on October 1, 2014.) Upon evaluation of this provision, the issuance of the shares could be treated as stock compensation and accounted for under the liability method from the date of initial issuance. This treatment would require the recognition of Non-Cash Stock Compensation Expense and a related liability in the Company’s financial statements. The amount of the periodic expense and associated liability would be based on the estimated fair market value of the shares for the periods being reported. The Company is currently evaluating the accounting treatment and may restate previously reported financial statements for all periods if the amount of Stock Compensation expense is determined to be material, including the current quarter and, if necessary, the previously audited financial statements for the years ended December 31, 2013 and 2012.
	As a consequence of the March 18, 2014 option agreements, if the liability method is deemed appropriate, the Company will continue the liability accounting method (expense recognition and resulting liability) until the agreements surrounding these shares expire or the shares are purchased by the Company.
	Management believes the results of operations and cash flows reported herein, and those of previous periods, are fairly stated in all material respects.
	The independent accountants have not completed their review of the current quarter’s financial statements herein.
	On October 7, 2012, the Company filed a certificate of designation with the Secretary of State of Nevada to designate 1,000,000 shares of Series C Convertible Preferred Stock, at $0.0001 par value per share. The Series C shares were convertible into shares of Common Stock by the quotient of 1 divided by the product of 0.80 multiplied by the market price of the Company’s Common Stock at the date of conversion. The Series C shares also included voting rights of 25 votes for every share of Series C Preferred Stock and were entitled to dividends at the same time any dividend was paid or declared on any shares of the Company’s Common Stock. Pursuant to their terms, all of the shares of Series C Preferred Stock were converted into shares of Common Stock on December 31, 2012.
	On March 17, 2014, the Company filed a Certificate of Designation with the Secretary of State of Nevada authorizing up to 200,000 shares of Series D Convertible Preferred Stock at $0.0001 par value per share ("Series D Preferred Stock"). Each share of Series D Preferred Stock is convertible into the number of shares of Common Stock equal to the quotient of 5 divided by the product of 0.80 multiplied by the market price, as defined in Certificate of Designation, of the Company’s Common Stock at the date of conversion. After the earlier of the date the trading volume of the Common Stock exceeds an aggregate of 3,000,000 shares in any 30 day period or the date the Company sells shares of Common Stock in a firm commitment underwritten public offering with aggregate gross proceeds of at least $30,000,000, each share of Series D Preferred Stock shall be convertible into the number of shares of Common Stock equal to the quotient of (i) 5 divided by (ii) the market price of the Common Stock. All shares of Series D Preferred Stock outstanding on the second anniversary of the original issuance date shall be automatically converted into shares of Common Stock.
	The Series D shares also include voting rights of 1 vote for every share of Series D Preferred Stock and are entitled to dividends, at the same time any dividend is paid or declared on any shares of the Company’s Common Stock The dividends are to be in an amount equal to the amount such holder would have received if the Series D Preferred Stock were converted to Common Stock. As of September 30, 2014 and December 31, 2013, there were 200,000 shares and no shares of Series D Preferred Stock outstanding, respectively.
	On August 21, 2014, the Company filed a Certificate of Designation with the Secretary of State of Nevada authorizing 100,000 shares of Series E Convertible Preferred Stock at a par value of $.0001 per share. The Series E shares are convertible into the number of shares of Common Stock equal to the quotient of 8 divided by the average market price of the Company’s Common Stock for thirty trading days prior to the date of conversion, multiplied by the number of Series E shares being converted. Any Series E shares which remain outstanding on August 28, 2016 will be automatically converted into Common Stock using the prescribed formula. The Series E shares also include voting rights of 1 vote for every share of Series E Preferred Stock and are entitled to dividends at the same time any dividend is paid or declared on any shares of the Company’s Common Stock. The dividends are to be in an amount equal to the amount such holder would have received if the Series E Preferred Stock were converted to Common Stock at the same time any dividend is paid or declared on any shares of the Company’s Common Stock. As of September 30, 2014 and December 31, 2013, there were 100,000 shares and no shares of Series E Preferred Stock outstanding, respectively.
	Preferred Stock
	During the nine months ended September 30, 2014 and 2013, the Series B preferred shareholders earned dividends totaling $3,815,719 and $1,396,238, respectively.
	On March 18, 2014, 200,000 shares of Series D Preferred Stock of the Company were issued to the previous owners of Clinlab pursuant to a stock purchase agreement whereby the Company purchased all of the outstanding stock of Clinlab (See Note 9 – Business Combinations).
	On August 28, 2014, 100,000 shares of Series E Preferred Stock of the Company were issued to the previous owner of Epinex pursuant to a stock purchase agreement whereby the Company purchased all of the outstanding stock of Epinex (See Note 9 – Business Combinations).
	Common Stock
	During the nine months ended September 30, 2014, the Company issued an aggregate of 285,000 shares of the Company’s restricted common stock. The Company issued an aggregate of 210,000 shares under the Medytox Solutions, Inc. 2013 Incentive Compensation Plan to six management executives and one consultant as partial payment of bonuses which were accrued at December 31, 2013. The shares were valued at $2.50, based on the price of shares sold to investors, for a total of $525,000. An aggregate of 65,000 shares were issued to two employees pursuant to employment agreements, valued at $2.50, based on the price of shares sold to investors, for a total of $162,500. A total of 10,000 shares were issued to GlobalOne in connection with the acquisition of certain assets, valued at $2.50, based on the price of shares sold to investors, for a total of $25,000.
	On September 11, 2014, William Forhan resigned as Chief Executive Officer and Chairman and returned 1,241,550 restricted common shares to the Company, which were then retired. Mr. Forhan remains the owner of 1,241,551 restricted common shares.
	2013 Equity Plan
	On September 25, 2013, the Company’s board of directors approved and adopted the Medytox Solutions, Inc. 2013 Incentive Compensation Plan (the “2013 Plan”). The 2013 Plan was approved by a majority of stockholders of the Company on November 22, 2013. The 2013 Plan provides for the grant of shares of common stock, options, performance shares, performance units, restricted stock, stock appreciation rights and other awards.
	The following summarizes activity under the 2013 Plan for the nine months ended September 30, 2014:
	Shares approved for issuance at plan inception			5,000,000
	Options granted in 2014			(1,435,000	)
	Options cancelled in 2014			10,000
	Restricted shares issued in 2014			(210,000	)
	Balance at September 30, 2014			3,365,000
	Stock Options
	The following summarizes options outstanding at December 31, 2013 and option activity for the nine months ended September 30, 2014:
														Weighted
			Common Stock Options Outstanding											average
			Employees and				Non-							exercise
			Directors				employees				Total			price
	Balance at December 31, 2013			20,150,000				3,020,000				23,170,000		$	5.33
	Options granted			1,435,000				–				1,435,000			2.76
	Options cancelled or expired			(210,000	)			–				(210,000	)		2.5
	Balance at September 30, 2014			21,375,000				3,020,000				24,395,000		$	5.06
	The following table summarizes information with respect to stock options outstanding and exercisable by employees and directors at September 30, 2014:
					Options outstanding													Options vested and exercisable
									Weighted
									average				Weighted							Weighted
									remaining				average			Aggregate				average	Aggregate
					Number				contractual				exercise			intrinsic		Number		exercise	intrinsic
	Exercise price				outstanding				life (years)				price			value		vested		price	value
	$2.50					8,625,000				3.76			$2.50			$	–		7,962,500	$2.50	$	–
	$5.00					6,750,000				3.24			$5.00				–		6,600,000	$5.00		–
	$10.00					6,000,000				8.26			$10.00				–		6,000,000	$10.00		–
						21,375,000							$5.39			$	–		20,562,500	$5.49	$	–
	The following table summarizes information with respect to stock options outstanding and exercisable by non-employees at September 30, 2014:
					Options outstanding													Options vested and exercisable
									Weighted
									average				Weighted							Weighted
									remaining				average			Aggregate				average	Aggregate
					Number				contractual				exercise			intrinsic		Number		exercise	intrinsic
	Exercise price				outstanding				life (years)				price			value		vested		price	value
	$2.50					1,020,000				3.2			$2.50			$	–		1,020,000	$2.50	$	–
	$5.00					1,000,000				3.25			$5.00				–		1,000,000	$5.00		–
	$10.00					1,000,000				8.26			$10.00				–		1,000,000	$10.00		–
						3,020,000							$5.81			$	–		3,020,000	$5.81	$	–
	During the nine months ended September 30, 2014, the Company issued options to purchase a total of 100,000 shares of the Company’s common stock to an employee pursuant to terms of an employment agreement. These options have contractual lives of two years and were valued at an average grant date fair value of $0.25 per option, or $25,000, using the Black-Scholes Option Pricing Model with the following assumptions:
	Stock price	$2.50
	Expected term	1 year
	Expected volatility	24.43%
Risk free interest rate	0.30%
Dividend yield	0
The stock price was based on the price of shares sold to investors and volatility was based on comparable volatility of other companies since the Company had no significant historical volatility. As the 100,000 options were vested as of September 30, 2014, $25,000 of stock-based compensation was recorded for the nine months ended September 30, 2014.
During the nine months ended September 30, 2014, the Company issued options to purchase a total of 1,035,000 shares of the Company’s common stock to various employees. These options have contractual lives of ten years and were valued at an average grant date fair value of $0.70 per option, or $724,500, using the Black-Scholes Option Pricing Model with the following assumptions:
Stock price	$2.50
Expected term	5.375 years
Expected volatility	27.72%
Risk free interest rate	1.46%
Dividend yield	0
The stock price was based on the price of shares sold to investors and volatility was based on comparable volatility of other companies since the Company had no significant historical volatility. As of September 30, 2014, 517,500 of these options had vested and the Company recognized $358,750 of stock-based compensation expense the nine and three months ended September 30, 2014.
During the nine months ended September 30, 2014, the Company issued options to purchase a total of 300,000 shares of the Company’s common stock to a director. These options have contractual lives of four years and were valued at an average grant date fair value of $0.18 per option, or $54,000, using the Black-Scholes Option Pricing Model with the following assumptions:
Stock price	$2.50
Expected term	2 years
Expected volatility	24.43%
Risk free interest rate	0.43%
Dividend yield	0
The stock price was based on the price of shares sold to investors and volatility was based on comparable volatility of other companies since the Company had no significant historical volatility. As of September 30, 2014, 200,000 of these options had vested and the Company recognized $36,000 of stock-based compensation expense the nine and three months ended September 30, 2014.
As of September 30, 2014, there were unrecognized compensation costs of $416,750 related to stock options. The Company expects to recognize those costs over a weighted average period of .35 years as of September 30, 2014. Future option grants will increase the amount of compensation expense to be recorded in these periods.
Warrants
The following table summarizes warrant transactions for the nine months ended September 30, 2014:
										Weighted
						Weighted				average
						average				remaining			Aggregate
		Number				exercise				contractual			intrinsic
		of warrants				price				term (years)			value
Granted in 2013			346,400			$	3.22
Outstanding at December 31, 2013 and September 30, 2014			346,400			$	3.22				0.32		$	–
Exercisable at December 31, 2013 and September 30, 2014			346,400			$	3.22				0.32		$	–
Weighted Average Grant Date Fair Value						$	0.25
During the nine months ended September 30, 2013, the Company issued warrants to purchase a total of 46,400 shares of the Company’s common stock in conjunction with sales of Units. These warrants have contractual lives of twenty-four months and were valued at a grant date fair value of $-0- per warrant using the Black-Scholes Option Pricing Model with the following assumptions:
Stock price	$0.01
Contractual term	24 months
Expected volatility	29.13%
Risk free interest rate	0.15%
Dividend yield	0
During the nine months ended September 30, 2013, the Company issued warrants to purchase a total of 300,000 shares of the Company’s common stock to two individuals in connection with obligations entered into by the Company’s subsidiaries. These warrants have contractual lives of two years and were valued at an average grant date fair value of $0.283 per warrant, or $85,000, using the Black-Scholes Option Pricing Model with the following assumptions:
Stock price	$2.50
Contractual term	2 years
Expected volatility	29.13%
Risk free interest rate	0.27%
Dividend yield	0
The stock price was based on the price of shares sold to investors and volatility was based on comparable volatility of other companies since the Company had no significant historical volatility. The $85,000 was expensed as stock-based consulting fees for the nine months ended September 30, 2013.
Basic and Diluted Income per Share
The Company computes income per share in accordance with ASC 260, "Earnings per Share", which requires presentation of both basic and diluted earnings per share (“EPS”) on the face of the statement of operations. Basic EPS is computed by dividing income available to common shareholders by the weighted average number of shares outstanding during the period. Diluted EPS gives effect to all potential dilutive equivalent shares of common stock outstanding during the period using the treasury stock method and convertible debt and convertible preferred stock using the if-converted method. In computing diluted EPS, the average stock price for the period is used in determining the number of shares assumed to be purchased from the exercise of stock options, convertible debt, convertible preferred stock, or warrants.
Basic and Diluted EPS were calculated as follows:
		Three Months Ended								Nine Months Ended
		September 30,								September 30,
		2014				2013				2014			2013
Basic:
Numerator - net income available to common stockholders		$	2,339,607			$	1,891,218			$	7,718,514		$	2,744,602
Denominator - weighted-average shares outstanding			30,281,386				29,692,110				30,186,893			29,610,287
Net income per share - Basic		$	0.08			$	0.06			$	0.26		$	0.09
Diluted:
Numerator:
Net income available to common stockholders		$	2,339,607			$	1,891,218			$	7,718,514		$	2,744,602
Interest expense on convertible debt, net of taxes			3,750				13,285				11,250			39,856
		$	2,343,357			$	1,904,503			$	7,729,764		$	2,784,458
Denominator:
Weighted-average shares outstanding			30,281,386				29,692,110				30,186,893			29,610,287
Weighted-average equivalent shares from convertible debt			222,222				322,222				222,222			245,706
Weighted-average equivalent shares from Series C convertible preferred stock			–				203,233				–			203,233
Weighted-average equivalent shares from Series D convertible preferred stock			200,000				–				143,590			–
Weighted-average equivalent shares from Series E convertible preferred stock			38,043				–				12,821			–
			30,741,651				30,217,565				30,565,526			30,059,226
Net income per share - Diluted		$	0.08			$	0.06			$	0.25		$	0.09
Diluted EPS excludes all dilutive potential shares if their effect is anti-dilutive. As of September 30, 2014 and 2013, the following potential common stock equivalents were excluded from the calculation of Diluted EPS as their effect was anti-dilutive:
		September 30,
		2014				2013
Stock options outstanding			24,395,000				23,170,000
Warrants outstanding			346,400				346,400
			24,741,400				23,516,400

8_Income_Taxes

8. Income Taxes	9 Months Ended
	Sep. 30, 2014
Income Tax Disclosure [Abstract]	'
8. Income Taxes	'
	Significant components of the income tax provision are summarized as follows:
		September 30,
		2014			2013
	Current provision:
	Federal	$	5,300,405		$	2,042,400
	State		887,800			218,100
	Deferred provision:
	Federal		959,500			(546,300	)
	State		102,600			(58,300	)
		$	7,250,305		$	1,655,900
	A reconciliation of the statutory federal income tax rate to the Company’s effective income tax rate on income before income taxes for the nine months ended September 30, 2014 and 2013 is as follows:
		September 30,
		2014			2013
	Expected federal income tax at 34% statutory rate		35.00%			34.00%
	State income taxes		3.50%			3.60%
	Permanent differences		0.10%			0.00%
	Change in valuation allowance		0.00%			0.00%
			38.60%			37.60%
	The Company provides for income taxes using the liability method in accordance with FASB ASC Topic 740 “Income Taxes”. Deferred income taxes arise from the differences in the recognition of income and expenses for tax purposes. Deferred tax assets and liabilities are comprised of the following at September 30, 2014 and December 31, 2013:
		September 30,			December 31,
		2014			2013
	Deferred income tax assets:
	Allowance for bad debts	$	–		$	1,362,900
	Accrued compensation		686,700			385,700
	Stock options		318,800			170,300
	Total deferred income tax assets	$	1,005,500		$	1,918,900
	Deferred income tax liabilities:
	Property and equipment	$	(105,000	)	$	(76,100	)
	Intangible amortization		(255,800	)		(136,000	)
	Total deferred income tax liabilities	$	(360,800	)	$	(212,100	)
	Net deferred income taxes:
	Current		686,700			1,748,600
	Non-current		(42,000	)		(41,800	)
		$	644,700		$	1,706,800
	Management has reviewed the provisions regarding assessment of their valuation allowance on deferred tax assets and based on that criteria determined that it will have sufficient taxable income to realize those assets. Therefore, management has assessed the realization of the deferred tax assets and has determined that it is more likely than not that they will be realized.
	The Company recognizes the consolidated financial statement impact of a tax position only after determining that the relevant tax authority would more likely than not sustain the position following an audit. For tax positions meeting the more-likely-than–not threshold, the amount recognized in the consolidated financial statements is the largest benefit that has a greater than 50 percent likelihood of being realized upon ultimate settlement with the relevant tax authority.

9_Business_Combinations

9. Business Combinations	9 Months Ended
	Sep. 30, 2014
Business Combinations [Abstract]	'
9. Business Combinations	'
	The Company completed three acquisitions during the nine months ended September 30, 2014 and two during the year ended December 31, 2013. The Company accounted for the assets, liabilities and ownership interests in accordance with the provisions of FASB ASC 805 “Business Combinations”. As such, the recorded assets and liabilities acquired have been recorded at fair value and any difference in the net asset values and the consideration given has been recorded as a gain on acquisition or as goodwill.
	Goodwill was attributable to the following subsidiaries as of September 30, 2014 and December 31, 2013:
		September 30,			December 31,
		2014			2013
	Medical Billing Choices, Inc.	$	1,202,112		$	1,202,112
	PB Laboratories, LLC		107,124			107,124
	Biohealth Medical Laboratory, Inc.		116,763			116,763
	Clinlab, Inc.		2,261,532			–
	Medical Mime, Inc. (GlobalOne Information Technologies, LLC)		176,816			–
	Epinex Diagnostic Laboratories Inc.		1,453,000			–
		$	5,317,347		$	1,425,999
	The goodwill attributed to each of Clinlab, Inc. and Epinex Diagnostics Laboratories, Inc. and the assets acquired from GlobalOne Information Technologies, LLC, is subject to adjustment by management as described below.
	Epinex Diagnostic Laboratories, Inc.
	On August 26, 2014, the Company, through its subsidiary, MDI, purchased all of the outstanding stock of Epinex from an unrelated party. The purchase price was an aggregate of $1,300,000, $100,000 in cash, $400,000 loan payable, and 100,000 shares of Series E Preferred Stock of the Company, currently convertible into $800,000 of common stock of the Company at the date of conversion.
	The following table summarizes the consideration given for Epinex and the fair values of the assets acquired and liabilities assumed recognized at the acquisition date. Management has retained a third party valuation firm to assist in the valuation the identifiable intangible assets acquired and the equity portion of the consideration given to the seller.  Until the valuation is complete and final values are assigned to the identifiable intangible assets acquired, the entire amount of the excess of the estimated consideration given over the working capital acquired, has been provisionally allocated to goodwill.
	Consideration Given:
	Cash	$	100,000
	Notes Payable		400,000
	Series E Preferred Stock		800,000
	Total consideration	$	1,300,000
	Fair value of identifiable assets acquired and liabilities assumed:
	Accounts receivable	$	80,000
	Property and equipment		27,000
	Accounts payable and accrued expenses		(260,000	)
	Identified intangible assets		–
	Total identifiable net assets		(153,000	)
	Goodwill and unidentified intangible assets		1,453,000
		$	1,300,000
	GlobalOne Information Technologies, LLC
	On May 23, 2014, the Company, through its subsidiary, Mime, purchased certain net assets, primarily consisting of software, of GlobalOne. The purchase price was an aggregate of $675,000, $500,000 in cash, 10,000 shares of Common Stock, and $150,000 in cash payable six months after the date of closing.
	The following table summarizes the consideration given for the net assets of GlobalOne and the fair values of the assets acquired and liabilities assumed recognized at the acquisition date. Management has retained a third party valuation firm to assist in the valuation the identifiable intangible assets acquired and the equity portion of the consideration given to the seller.  Until the valuation is complete and final values are assigned to the identifiable intangible assets acquired, the entire amount of the excess of the estimated consideration given over the working capital acquired, has been provisionally allocated to goodwill.
	Consideration Given:
	Cash	$	500,000
	Common stock		25,000
	Acquisition liability		150,000
	Total consideration	$	675,000
	Fair value of identifiable assets acquired and liabilities assumed:
	Accounts receivable	$	93,270
	Accounts payable and accrued expenses		(95,086	)
	Software		500,000
	Identified intangible assets		–
	Total identifiable net assets		498,184
	Goodwill and unidentified intangible assets		176,816
		$	675,000
	Clinlab, Inc.
	On March 18, 2014, the Company, through its subsidiary, MIT, purchased all of the outstanding stock of Clinlab from two unrelated parties. The purchase price was an aggregate of $2,250,000, $1,000,000 in cash and 200,000 shares of Series D Preferred Stock of the Company, convertible into approximately $1,250,000 of common stock of the Company at the date of conversion.
	The following table summarizes the consideration given for Clinlab and the fair values of the assets acquired and liabilities assumed recognized at the acquisition date. Management has retained a third party valuation firm to assist in the valuation the identifiable intangible assets acquired and the equity portion of the consideration given to the seller.  Until the valuation is complete and final values are assigned to the identifiable intangible assets acquired, the entire amount of the excess of the estimated consideration given over the working capital acquired, has been provisionally allocated to goodwill.
	Consideration Given:
	Cash	$	1,000,000
	Series D Preferred Stock		1,250,000
	Contingent acquisition liability		54,017
	Total consideration	$	2,304,017
	Fair value of identifiable assets acquired and liabilities assumed:
	Cash	$	31,671
	Accounts receivable		54,017
	Prepaid expenses		241
	Security deposit		700
	Accounts payable and accrued expenses		(44,144	)
	Identified intangible assets		–
	Total identifiable net assets		42,485
	Goodwill and unidentified intangible assets		2,261,532
		$	2,304,017

10_Commitments_and_Contingenci

10. Commitments and Contingencies	9 Months Ended
	Sep. 30, 2014
Commitments and Contingencies Disclosure [Abstract]	'
10. Commitments and Contingencies	'
	Legal Matters
	During the course of business, litigation commonly occurs.  From time to time the Company may be a party to litigation matters involving claims against the Company. The Company operates in a highly regulated industry and employs personnel which may inherently lend itself to legal matters.  Management is aware that litigation has associated costs and that results of adverse litigation verdicts could have a material effect on the Company's financial position or results of operations. Management, in consultation with legal counsel, has addressed known assertions and unasserted claims below.
	On July 2, 2013, a jury awarded Medytox Institute of Laboratory Medicine, Inc., our wholly-owned subsidiary ("MILM"), $2,906,844 on its breach of contract claim against Trident Laboratories, Inc. and its shareholders and awarded Seamus Lagan $750,000 individually against Christopher Hawley for defamatory postings on the internet. The jury rejected every claim made against the MILM parties. All appeals have been dismissed. Because of the uncertainties as to the collectability of amounts awarded, no amounts have been recorded by the Company.
	The Company filed an action on February 14, 2014 in the United States District Court for the Southern District of Florida against Reginald Samuels and Ralph Perricelli seeking, among other things, a declaration that the convertible debentures in the aggregate amount of $500,000 that the Company issued to Mr. Samuels and Mr. Perricelli as part of the consideration for the purchase of their interests in International Technologies, LLC are null and void. Mr. Samuels and Mr. Perricelli have been served and the litigation is ongoing.
	On October 21, 2013, Mr. Samuels filed a complaint in the Superior Court of New Jersey (Bergen County) against the Company and Medytox Diagnostics, Inc. alleging breach of contract under his employment agreement and the agreement under which International Technologies, LLC was acquired; unjust enrichment; fraud; intentional and negligent misrepresentation; and breach of an implied duty of good faith and fair dealing and seeking an accounting. On December 20, 2013, Mr. Perricelli filed a similar action in the same court. The Company believes all these claims are without merit.
	The action filed by Mr. Samuels has been removed to the federal court in the District of New Jersey. The action filed by Mr. Perricelli has been transferred to the Southern District of Florida.

11_Subsequent_Events

11. Subsequent Events	9 Months Ended
	Sep. 30, 2014
Subsequent Events [Abstract]	'
11. Subsequent Events	'
	The Company has evaluated subsequent events through the date the financial statements were issued and filed with the SEC. The Company has determined that there are no subsequent events that warrant disclosure or recognition in the consolidated financial statements.

1_Organization_and_Presentatio1

1. Organization and Presentation (Policies)	9 Months Ended
	Sep. 30, 2014
Organization, Consolidation and Presentation of Financial Statements [Abstract]	'
Organization	'
	Organization
	Medytox Solutions, Inc. (the “Company”) was incorporated in Nevada on July 20, 2005 as Casino Players, Inc. In the first half of 2011, Company management decided to reorganize the operations of the Company as a holding company to acquire and manage a number of companies in the medical services sector.
	On March 18, 2014, the Company's wholly-owned subsidiary, Medytox Information Technology, Inc. (“MIT”), purchased 100% of the stock of Clinlab, Inc. ("Clinlab"). Clinlab develops and markets laboratory information management systems.
	On May 9, 2014, the Company formed Medical Mime, Inc. (“Mime”), a Florida corporation, as a wholly-owned subsidiary.
	On May 23, 2014, Mime purchased certain net assets, primarily consisting of software, of GlobalOne Information Technologies, LLC (“GlobalOne”). GlobalOne developed software and provided services for the Electronic Health Records (“EHR”) segment of the medical industry.
	On August 26, 2014, the Company's wholly-owned subsidiary, Medytox Diagnostics, Inc. (“MDI”), purchased 100% of the stock of Epinex Diagnostics Laboratories, Inc. ("Epinex"), a clinical laboratory in Tustin, California.
Basis of Presentation	'
	Basis of Presentation
	The accompanying unaudited interim condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States (“U.S. GAAP”) for interim financial statement presentation and in accordance with Form 10-Q. Accordingly, they do not include all of the information and footnotes required in annual financial statements. In the opinion of management, the unaudited interim condensed consolidated financial statements contain all adjustments (consisting only of normal recurring accruals) necessary to present fairly the financial position and results of operations and cash flows for the interim periods reported in this Form 10-Q. The results of operations presented are not necessarily indicative of the results to be expected for any other interim period or for the entire year.
	These unaudited interim condensed consolidated financial statements should be read in conjunction with the 2013 audited annual financial statements included in the Annual Report on Form 10-K, filed with the U.S. Securities and Exchange Commission (“SEC”) on March 31, 2014.
	The historical accounting for the Company’s Series B Preferred shares is currently being evaluated. (See Note 7). Management believes that the unaudited condensed financial statements herein and those previously reported are fairly stated in all material respects.
	The independent accountants have not completed their review of the current quarter’s financial statements herein.
Contractual allowances and doubtful accounts	'
	Contractual Allowances and Doubtful Accounts
	Accounts receivable are presented net of allowances for uncollectible amounts of $12,262,894 and $3,621,814 at September 30, 2014 and December 31, 2013, respectively.
Reclassifications	'
	Reclassifications
	The provision for bad debts has been classified on the statements of operations as a reduction of revenues for all periods presented herein. Certain other items on the statements of operations for the three and nine months ended September 30, 2013 and the statement of cash flows for the nine months ended September 30, 2013 have been reclassified to conform to current period presentation.

2_Disputed_Subsidiary_Tables

2. Disputed Subsidiary (Tables)	9 Months Ended
	Sep. 30, 2014
Organization, Consolidation and Presentation of Financial Statements [Abstract]	'
Assets and liabilities of the subsidiary	'
		September 30,		December 31,
		2014		2013
	Total assets	$	-0-	$	1,367,796
	Total liabilities	$	-0-	$	1,104,063

3_LongLived_Assets_Tables

3. Long-Lived Assets (Tables)	9 Months Ended
	Sep. 30, 2014
Property, Plant and Equipment [Abstract]	'
Property and equipment	'
		September 30,			December 31,
		2014			2013
	Medical equipment	$	824,328		$	655,125
	Equipment		256,918			111,265
	Equipment under capital leases (See Note 6 - Capital Lease Obligations)		3,008,613			980,948
	Furniture		234,199			206,587
	Leasehold improvements		886,860			243,983
	Vehicles		292,509			177,534
	Computer equipment		475,161			235,507
	Software		890,179			285,175
			6,868,767			2,896,124
	Less accumulated depreciation		(1,540,470	)		(739,743	)
	Property and equipment, net	$	5,328,297		$	2,156,381

4_Notes_Payable_Tables

4. Notes Payable (Tables)	9 Months Ended
	Sep. 30, 2014
Debt Disclosure [Abstract]	'
Schedule of Notes Payable	'
		September 30,			December 31,
		2014			2013
	Convertible debenture for working capital, dated September 15, 2011, in the amount of $500,000 and bearing interest at 20%. The note was convertible at $2.50 per share. The due date of the note was extended from October 31, 2013 to February 5, 2014 by the lender. The note was paid in full on February 5, 2014.	$	–		$	100,000
	Loan from TCA. Principal of $2,475,000 and $2,475,000, respectively, payable by January 15, 2014.  The note was extended from January 15, 2014 to September 15, 2014 and was secured by all assets of the Company and its subsidiaries (other than Trident and MBC). See "TCA Global" below.		–			2,475,000
	Acquisition note No.1 to former shareholder of Alethea Laboratories, Inc. in the amount of $287,500 at 0% interest, with payments of $50,000 due quarterly starting April 1, 2013.		–			150,000
	Acquisition note No. 2 to former shareholder of Alethea Laboratories, Inc. in the amount of $287,500 at 0% interest, with payments of $50,000 due quarterly starting April 1, 2013.		–			150,000
	Loan from former shareholders of Alethea Laboratories, Inc. in the amount of $344,650 at 4% interest, with principal payments of $24,618 due monthly starting March 15, 2013. The note was paid in full on April 1, 2014.		–			98,471
	Commercial loan with a finance company, dated December 20, 2012, in the original amount of $18,249 and bearing interest at 12.59%. Principal and interest payments in the amount of $364 were payable for 72 months ending on January 3, 2019. This note was secured by a lien on a vehicle with a carrying value of $16,623 at December 31, 2013. The note was paid in full on March 26, 2014.		–			15,845
	Commercial loan with a finance company, dated November 15, 2012, in the original amount of $18,008 and bearing interest at 15.07%. Principal and interest payments in the amount of $384 are payable for 72 months ending on November 30, 2018. This note was secured by a lien on a vehicle with a carrying value of $16,430 at December 31, 2013. The note was paid in full on March 26, 2014.		–			16,279
	Commercial loan with a finance company, dated November 28, 2012, in the original amount of $20,345 and bearing interest at 8.99%.  Principal and interest payments in the amount of $368 are payable for 72 months ending on January 12, 2019. This note was secured by a lien on a vehicle with a carrying value of $18,300 at December 31, 2013.  The note was paid in full on March 26, 2014.		–			17,676
	Acquisition convertible note No. 1 to former member of International Technologies, LLC in the amount of $250,000 at 5% interest and was due January 17, 2014.  The note was convertible into the Company's common stock at a ten percent (10%) discount to the average market price for the thirty days prior to conversion.  The note is discounted for its unamortized beneficial conversion feature of $-0- and $1,639 at September 30, 2014 and December 31, 2013, respectively.  See "Acquisition Convertible Notes" below.		250,000			248,361
	Acquisition convertible note No. 2 to former member of International Technologies, LLC in the amount of $250,000 at 5% interest and was due January 17, 2014.  The note was convertible into the Company's common stock at a ten percent (10%) discount to the average market price for the thirty days prior to conversion. The note is discounted for its unamortized beneficial conversion feature of $-0- and $1,639 at September 30, 2014 and December 31, 2013, respectively.   See "Acquisition Convertible Notes" below.		250,000			248,361
	Loan from former member of International Technologies, LLC in the remaining amount of $416,667 at the date of acquisition, at 1% interest, with principal payments of $83,333 due quarterly starting June 7, 2013.  The note was paid in full on June 6, 2014.		–			166,668
	Loan from former member of International Technologies, LLC in the remaining amount of $112,500 at the date of acquisition, at 1% interest, with principal payments of $22,500 due quarterly starting June 7, 2013.  The note was paid in full on June 6, 2014.		–			45,000
	Loan payable to former shareholder of Epinex Diagnostic Laboratories, Inc. in the amount of $400,000, at 0% interest, with principal payments of $100,000 due in periodic installments from November 26, 2014 through February 26, 2016.		400,000			–
			900,000			3,731,661
	Less current portion		(800,000	)		(3,689,554	)
	Notes payable, net of current portion	$	100,000		$	42,107

6_Capital_Lease_Obligations_Ta

6. Capital Lease Obligations (Tables)	9 Months Ended
	Sep. 30, 2014
Debt Disclosure [Abstract]	'
Capital Lease	'
		September 30,			December 31,
		2014			2013
	Medical equipment	$	3,008,613		$	980,948
	Less accumulated depreciation		(689,135	)		(364,726	)
	Net	$	2,319,478		$	616,222
Aggregate future minimum rentals under capital leases	'
	December 31,
	2014	$	227,810
	2015		911,238
	2016		771,302
	2017		662,897
	2018		75,667
	Thereafter		68,186
	Total		2,717,100
	Less interest		371,772
	Present value of minimum lease payments		2,345,328
	Less current portion of capital lease obligations		727,601
	Capital lease obligations, net of current portion	$	1,617,727

7_Stockholders_Equity_Tables

7. Stockholders' Equity (Tables)	9 Months Ended
	Sep. 30, 2014
Equity [Abstract]	'
Summary of plan activity	'
	Shares approved for issuance at plan inception			5,000,000
	Options granted in 2014			(1,435,000	)
	Options cancelled in 2014			10,000
	Restricted shares issued in 2014			(210,000	)
	Balance at September 30, 2014			3,365,000
Options outstanding	'
														Weighted
			Common Stock Options Outstanding											average
			Employees and				Non-							exercise
			Directors				employees				Total			price
	Balance at December 31, 2013			20,150,000				3,020,000				23,170,000		$	5.33
	Options granted			1,435,000				–				1,435,000			2.76
	Options cancelled or expired			(210,000	)			–				(210,000	)		2.5
	Balance at September 30, 2014			21,375,000				3,020,000				24,395,000		$	5.06
Schedule of stock option activity	'
	The following table summarizes information with respect to stock options outstanding and exercisable by employees and directors at September 30, 2014:
					Options outstanding													Options vested and exercisable
									Weighted
									average				Weighted							Weighted
									remaining				average			Aggregate				average	Aggregate
					Number				contractual				exercise			intrinsic		Number		exercise	intrinsic
	Exercise price				outstanding				life (years)				price			value		vested		price	value
	$2.50					8,625,000				3.76			$2.50			$	–		7,962,500	$2.50	$	–
	$5.00					6,750,000				3.24			$5.00				–		6,600,000	$5.00		–
	$10.00					6,000,000				8.26			$10.00				–		6,000,000	$10.00		–
						21,375,000							$5.39			$	–		20,562,500	$5.49	$	–
	The following table summarizes information with respect to stock options outstanding and exercisable by non-employees at September 30, 2014:
					Options outstanding													Options vested and exercisable
									Weighted
									average				Weighted							Weighted
									remaining				average			Aggregate				average	Aggregate
					Number				contractual				exercise			intrinsic		Number		exercise	intrinsic
	Exercise price				outstanding				life (years)				price			value		vested		price	value
	$2.50					1,020,000				3.2			$2.50			$	–		1,020,000	$2.50	$	–
	$5.00					1,000,000				3.25			$5.00				–		1,000,000	$5.00		–
	$10.00					1,000,000				8.26			$10.00				–		1,000,000	$10.00		–
						3,020,000							$5.81			$	–		3,020,000	$5.81	$	–
Option assumptions	'
	During the nine months ended September 30, 2014, the Company issued options to purchase a total of 100,000 shares of the Company’s common stock to an employee pursuant to terms of an employment agreement. These options have contractual lives of two years and were valued at an average grant date fair value of $0.25 per option, or $25,000, using the Black-Scholes Option Pricing Model with the following assumptions:
	Stock price	$2.50
	Expected term	1 year
	Expected volatility	24.43%
	Risk free interest rate	0.30%
	Dividend yield	0
	During the nine months ended September 30, 2014, the Company issued options to purchase a total of 1,035,000 shares of the Company’s common stock to various employees. These options have contractual lives of ten years and were valued at an average grant date fair value of $0.70 per option, or $724,500, using the Black-Scholes Option Pricing Model with the following assumptions:
	Stock price	$2.50
	Expected term	5.375 years
	Expected volatility	27.72%
	Risk free interest rate	1.46%
	Dividend yield	0
	During the nine months ended September 30, 2014, the Company issued options to purchase a total of 300,000 shares of the Company’s common stock to a director. These options have contractual lives of four years and were valued at an average grant date fair value of $0.18 per option, or $54,000, using the Black-Scholes Option Pricing Model with the following assumptions:
	Stock price	$2.50
	Expected term	2 years
	Expected volatility	24.43%
	Risk free interest rate	0.43%
	Dividend yield	0
Warrant transactions	'
											Weighted
							Weighted				average
							average				remaining			Aggregate
			Number				exercise				contractual			intrinsic
			of warrants				price				term (years)			value
	Granted in 2013			346,400			$	3.22
	Outstanding at December 31, 2013 and September 30, 2014			346,400			$	3.22				0.32		$	–
	Exercisable at December 31, 2013 and September 30, 2014			346,400			$	3.22				0.32		$	–
	Weighted Average Grant Date Fair Value						$	0.25
Warrant assumption	'
	During the nine months ended September 30, 2013, the Company issued warrants to purchase a total of 46,400 shares of the Company’s common stock in conjunction with sales of Units. These warrants have contractual lives of twenty-four months and were valued at a grant date fair value of $-0- per warrant using the Black-Scholes Option Pricing Model with the following assumptions:
	Stock price	$0.01
	Contractual term	24 months
	Expected volatility	29.13%
	Risk free interest rate	0.15%
	Dividend yield	0
	During the nine months ended September 30, 2013, the Company issued warrants to purchase a total of 300,000 shares of the Company’s common stock to two individuals in connection with obligations entered into by the Company’s subsidiaries. These warrants have contractual lives of two years and were valued at an average grant date fair value of $0.283 per warrant, or $85,000, using the Black-Scholes Option Pricing Model with the following assumptions:
	Stock price	$2.50
	Contractual term	2 years
	Expected volatility	29.13%
	Risk free interest rate	0.27%
	Dividend yield	0
Basic and Diluted Income Per Share	'
			Three Months Ended								Nine Months Ended
			September 30,								September 30,
			2014				2013				2014			2013
	Basic:
	Numerator - net income available to common stockholders		$	2,339,607			$	1,891,218			$	7,718,514		$	2,744,602
	Denominator - weighted-average shares outstanding			30,281,386				29,692,110				30,186,893			29,610,287
	Net income per share - Basic		$	0.08			$	0.06			$	0.26		$	0.09
	Diluted:
	Numerator:
	Net income available to common stockholders		$	2,339,607			$	1,891,218			$	7,718,514		$	2,744,602
	Interest expense on convertible debt, net of taxes			3,750				13,285				11,250			39,856
			$	2,343,357			$	1,904,503			$	7,729,764		$	2,784,458
	Denominator:
	Weighted-average shares outstanding			30,281,386				29,692,110				30,186,893			29,610,287
	Weighted-average equivalent shares from convertible debt			222,222				322,222				222,222			245,706
	Weighted-average equivalent shares from Series C convertible preferred stock			–				203,233				–			203,233
	Weighted-average equivalent shares from Series D convertible preferred stock			200,000				–				143,590			–
	Weighted-average equivalent shares from Series E convertible preferred stock			38,043				–				12,821			–
				30,741,651				30,217,565				30,565,526			30,059,226
	Net income per share - Diluted		$	0.08			$	0.06			$	0.25		$	0.09
Antidilutive securities	'
			September 30,
			2014				2013
	Stock options outstanding			24,395,000				23,170,000
	Warrants outstanding			346,400				346,400
				24,741,400				23,516,400

8_Income_Taxes_Tables

8. Income Taxes (Tables)	9 Months Ended
	Sep. 30, 2014
Income Tax Disclosure [Abstract]	'
Income tax provision	'
		September 30,
		2014			2013
	Current provision:
	Federal	$	5,300,405		$	2,042,400
	State		887,800			218,100
	Deferred provision:
	Federal		959,500			(546,300	)
	State		102,600			(58,300	)
		$	7,250,305		$	1,655,900
Reconciliation of the statutory federal income tax rate	'
		September 30,
		2014			2013
	Expected federal income tax at 34% statutory rate		35.00%			34.00%
	State income taxes		3.50%			3.60%
	Permanent differences		0.10%			0.00%
	Change in valuation allowance		0.00%			0.00%
			38.60%			37.60%
Deferred Tax Liability	'
		September 30,			December 31,
		2014			2013
	Deferred income tax assets:
	Allowance for bad debts	$	–		$	1,362,900
	Accrued compensation		686,700			385,700
	Stock options		318,800			170,300
	Total deferred income tax assets	$	1,005,500		$	1,918,900
	Deferred income tax liabilities:
	Property and equipment	$	(105,000	)	$	(76,100	)
	Intangible amortization		(255,800	)		(136,000	)
	Total deferred income tax liabilities	$	(360,800	)	$	(212,100	)
	Net deferred income taxes:
	Current		686,700			1,748,600
	Non-current		(42,000	)		(41,800	)
		$	644,700		$	1,706,800

9_Business_Combinations_Tables

9. Business Combinations (Tables)	9 Months Ended
	Sep. 30, 2014
Schedule of goodwill	'
		September 30,			December 31,
		2014			2013
	Medical Billing Choices, Inc.	$	1,202,112		$	1,202,112
	PB Laboratories, LLC		107,124			107,124
	Biohealth Medical Laboratory, Inc.		116,763			116,763
	Clinlab, Inc.		2,261,532			–
	Medical Mime, Inc. (GlobalOne Information Technologies, LLC)		176,816			–
	Epinex Diagnostic Laboratories Inc.		1,453,000			–
		$	5,317,347		$	1,425,999
Epinez Diagnostic Laboratories [Member]	'
Consideration given	'
	Consideration Given:
	Cash	$	100,000
	Notes Payable		400,000
	Series E Preferred Stock		800,000
	Total consideration	$	1,300,000
	Fair value of identifiable assets acquired and liabilities assumed:
	Accounts receivable	$	80,000
	Property and equipment		27,000
	Accounts payable and accrued expenses		(260,000	)
	Identified intangible assets		–
	Total identifiable net assets		(153,000	)
	Goodwill and unidentified intangible assets		1,453,000
		$	1,300,000
GlobalOne Information Technologies, LLC	'
Consideration given	'
	Consideration Given:
	Cash	$	500,000
	Common stock		25,000
	Acquisition liability		150,000
	Total consideration	$	675,000
	Fair value of identifiable assets acquired and liabilities assumed:
	Accounts receivable	$	93,270
	Accounts payable and accrued expenses		(95,086	)
	Software		500,000
	Identified intangible assets		–
	Total identifiable net assets		498,184
	Goodwill and unidentified intangible assets		176,816
		$	675,000
Clinlab, Inc.	'
Consideration given	'
	Consideration Given:
	Cash	$	1,000,000
	Series D Preferred Stock		1,250,000
	Contingent acquisition liability		54,017
	Total consideration	$	2,304,017
	Fair value of identifiable assets acquired and liabilities assumed:
	Cash	$	31,671
	Accounts receivable		54,017
	Prepaid expenses		241
	Security deposit		700
	Accounts payable and accrued expenses		(44,144	)
	Identified intangible assets		–
	Total identifiable net assets		42,485
	Goodwill and unidentified intangible assets		2,261,532
		$	2,304,017

1_Organization_and_Presentatio2

1. Organization and Presentation (Details Narrative) (USD $)	Sep. 30, 2014	Dec. 31, 2013
Organization, Consolidation and Presentation of Financial Statements [Abstract]	'	'
Allowance for doubtful accounts	$12,262,894	$3,621,814

2_Disputed_Subsidiary_Details

2. Disputed Subsidiary (Details) (USD $)	Sep. 30, 2014	Dec. 31, 2013
Organization, Consolidation and Presentation of Financial Statements [Abstract]	'	'
Assets of disputed subsidiary	$0	$1,367,796
Liabilities of disputed subsidiary	$0	$1,104,063

2_Disputed_Subsidiary_Details_

2. Disputed Subsidiary (Details Narrative) (USD $)	3 Months Ended		9 Months Ended
	Sep. 30, 2014	Sep. 30, 2013	Sep. 30, 2014	Sep. 30, 2013	Dec. 31, 2013
Legal fees	$0	$267,286	$94,217	$857,587	'
Gain on disposition	0	0	134,185	0	'
Disputed Subsidiary	'	'	'	'	'
Legal fees	0	267,286	94,217	857,587	'
Commisions payable on disputed subsidiary	'	'	'	'	389,135
Gain on disposition	'	'	$134,185	'	'

3_LongLived_Assets_Details

3. Long-Lived Assets (Details) (USD $)	Sep. 30, 2014	Dec. 31, 2013
Property and equipment, gross	$6,868,767	$2,896,124
Accumulated depreciation	-1,540,470	-739,743
Property and equipment, net	5,328,297	2,156,381
Medical equipment	'	'
Property and equipment, gross	824,328	655,125
Equipment	'	'
Property and equipment, gross	256,918	111,265
Equipment under capital leases	'	'
Property and equipment, gross	3,008,613	980,948
Furniture	'	'
Property and equipment, gross	234,199	206,587
Leasehold Improvements	'	'
Property and equipment, gross	886,860	243,983
Vehicles	'	'
Property and equipment, gross	292,509	177,534
Computer Equipment	'	'
Property and equipment, gross	475,161	235,507
Software	'	'
Property and equipment, gross	$890,179	$285,175

3_LongLived_Assets_Details_Nar

4. Notes Payable (Details) (USD $)	Sep. 30, 2014	Dec. 31, 2013
Notes payable, total	$900,000	$3,731,661
Less: current portion	-800,000	-3,689,554
Notes payable, net of current portion	100,000	42,107
Convertible debenture for working capital	'	'
Notes payable, total	0	100,000
Loan from TCA	'	'
Notes payable, total	0	2,475,000
Acquisition note 1 to Alethea	'	'
Notes payable, total	0	150,000
Acquisition note 2 to Alethea	'	'
Notes payable, total	0	150,000
Loan from former shareholders of Alethea	'	'
Notes payable, total	0	98,471
Commercial loan	'	'
Notes payable, total	0	15,845
Commercial loan 2	'	'
Notes payable, total	0	16,279
Commercial loan 3	'	'
Notes payable, total	0	17,676
Acquisition convertible note 1	'	'
Notes payable, total	250,000	248,361
Acquisition convertible note 2	'	'
Notes payable, total	250,000	248,361
Loan from former member Intl Technologies	'	'
Notes payable, total	0	166,668
Loan 2 from former member Intl Technologies	'	'
Notes payable, total	0	45,000
Loan Payable to former shareholder of Epinex [Member]	'	'
Notes payable, total	$400,000	$0

4_Notes_Payable_Details

4. Notes Payable (Details) (USD $)	Sep. 30, 2014	Dec. 31, 2013
Notes payable, total	$900,000	$3,731,661
Less: current portion	-800,000	-3,689,554
Notes payable, net of current portion	100,000	42,107
Convertible debenture for working capital	'	'
Notes payable, total	0	100,000
Loan from TCA	'	'
Notes payable, total	0	2,475,000
Acquisition note 1 to Alethea	'	'
Notes payable, total	0	150,000
Acquisition note 2 to Alethea	'	'
Notes payable, total	0	150,000
Loan from former shareholders of Alethea	'	'
Notes payable, total	0	98,471
Commercial loan	'	'
Notes payable, total	0	15,845
Commercial loan 2	'	'
Notes payable, total	0	16,279
Commercial loan 3	'	'
Notes payable, total	0	17,676
Acquisition convertible note 1	'	'
Notes payable, total	250,000	248,361
Acquisition convertible note 2	'	'
Notes payable, total	250,000	248,361
Loan from former member Intl Technologies	'	'
Notes payable, total	0	166,668
Loan 2 from former member Intl Technologies	'	'
Notes payable, total	0	45,000
Loan Payable to former shareholder of Epinex [Member]	'	'
Notes payable, total	$400,000	$0

5_Related_Party_Transactions_D

5. Related Party Transactions (Details Narrative)	Sep. 30, 2014	Dec. 31, 2013	Sep. 30, 2014
			Forhan [Member]
Restricted common stock returned, shares returned	'	'	1,241,550
Restricted common shares issued	29,036,386	29,996,386	1,241,551

6_Capital_Lease_Obligations_De

6. Capital Lease Obligations (Details - Capital leased equipment) (USD $)	Sep. 30, 2014	Dec. 31, 2013
Capital Lease Obligations [Abstract]	'	'
Medical equipment	$3,008,613	$980,948
Less accumulated depreciation	-689,135	-364,726
Equipment under capital leases	$2,319,478	$616,222

6_Capital_Lease_Obligations_De1

6. Capital Lease Obligations (Details - minimum lease payments) (USD $)	Sep. 30, 2014	Dec. 31, 2013
December 31,	'	'
2014	$227,810	'
2015	911,238	'
2016	771,302	'
2017	662,897	'
2018	75,667	'
Thereafter	68,186	'
Total	2,717,100	'
Less interest:	371,772	'
Present value of minimum lease payments	2,345,328	'
Less current portion of capital lease obligations	-727,601	-193,095
Capital lease obligations, net of current portion	$1,617,727	$405,718

6_Capital_Lease_Obligations_De2

6. Capital Lease Obligations (Details Narrative) (USD $)	9 Months Ended
	Sep. 30, 2014	Sep. 30, 2013
Debt Disclosure [Abstract]	'	'
Depreciation expense on assets under capital leases	$324,409	$98,340

7_Stockholders_Equity_Details_

7. Stockholders' Equity (Details - 2013 Plan activity) (USD $)	9 Months Ended
	Sep. 30, 2014
Stock Options	'
Options outstanding	'
Options outstanding, beginning balance	23,170,000
Options granted	1,435,000
Options exercised	0
Options cancelled or expired	-210,000
Options outstanding, ending balance	24,395,000
Weighted Average Exercise Price	'
Options outstanding, beginning balance	$5.33
Options granted	$2.76
Options cancelled or expired	$2.50
Options outstanding, ending balance	$5.06
Stock Options | Employees and Directors	'
Options outstanding	'
Options outstanding, beginning balance	20,150,000
Options granted	1,435,000
Options exercised	0
Options cancelled or expired	-210,000
Options outstanding, ending balance	21,375,000
Weighted Average Exercise Price	'
Options outstanding, ending balance	$5.39
Stock Options | Non-Employee	'
Options outstanding	'
Options outstanding, beginning balance	3,020,000
Options granted	0
Options exercised	0
Options cancelled or expired	0
Options outstanding, ending balance	3,020,000
2013 Equity Plan	'
Options outstanding	'
Options outstanding, beginning balance	5,000,000
Options granted	-1,435,000
Options cancelled or expired	10,000
Restricted shares issued	-210,000
Options outstanding, ending balance	3,365,000

7_Stockholders_Equity_Details_1

7. Stockholders' Equity (Details - Option activity) (Stock Options, USD $)	Sep. 30, 2014	Dec. 31, 2013	Sep. 30, 2014	Dec. 31, 2013	Sep. 30, 2014	Sep. 30, 2014	Sep. 30, 2014
			Employees and Directors	Employees and Directors	Exercise price $2.50	Exercise price $5.00	Exercise price $10.00
					Employees and Directors	Employees and Directors	Employees and Directors
Options Outstanding - Employees and Directors	'	'	'	'	'	'	'
Options outstanding	24,395,000	23,170,000	21,375,000	20,150,000	8,625,000	6,750,000	6,000,000
Weighted average remaining contractual life	'	'	'	'	'3 years 9 months 4 days	'3 years 2 months 26 days	'8 years 3 months 4 days
Weighted average exercise price - outstanding	$5.06	$5.33	$5.39	'	$2.50	$5	$10
Aggregate intrinsic value - outstanding	'	'	$0	'	$0	$0	$0
Options Vested and Exercisable - Employees and Directors	'	'	'	'	'	'	'
Options vested	'	'	20,562,500	'	7,962,500	6,600,000	6,000,000
Weighted average exercise price - vested and exercisable	'	'	$5.49	'	$2.50	$5	$10
Aggregate intrinsic value - vested and exercisable	'	'	$0	'	$0	$0	$0

7_Stockholders_Equity_Details_2

7. Stockholders' Equity (Details - Options outstanding and exercisable) (Stock Options, USD $)	Sep. 30, 2014	Dec. 31, 2013	Sep. 30, 2014	Sep. 30, 2014	Sep. 30, 2014	Sep. 30, 2014
			Non-Employee	Exercise price $2.50	Exercise price $5.00	Exercise price $10.00
				Non-Employee	Non-Employee	Non-Employee
Options Outstanding - Non-Employees	'	'	'	'	'	'
Options outstanding	24,395,000	23,170,000	'	1,020,000	1,000,000	1,000,000
Weighted average remaining contractual life	'	'	'	'3 years 2 months 12 days	'3 years 3 months	'8 years 3 months 4 days
Weighted average exercise price - outstanding	$5.06	$5.33	'	$2.50	$5	$10
Aggregate intrinsic value - outstanding	'	'	$0	$0	$0	$0
Options Vested and Exercisable - Non-Employees	'	'	'	'	'	'
Options vested	'	'	3,020,000	1,020,000	1,000,000	1,000,000
Weighted average exercise price - vested and exercisable	'	'	$5.81	$2.50	$5	$10
Aggregate intrinsic value - vested and exercisable	'	'	$0	$0	$0	$0

7_Stockholders_Equity_Details_3

7. Stockholders' Equity (Details - Assumptions) (Stock Options, USD $)	9 Months Ended
	Sep. 30, 2014
Employee	'
Stock price	$2.50
Contractual term	'1 year
Expected volatility	24.43%
Risk free interest rate	0.30%
Dividend yield	0.00%
Various Employee	'
Stock price	$2.50
Contractual term	'5 years 4 months 15 days
Expected volatility	27.72%
Risk free interest rate	1.46%
Dividend yield	0.00%
Director	'
Stock price	$2.50
Contractual term	'2 years
Expected volatility	24.43%
Risk free interest rate	0.43%
Dividend yield	0.00%

7_Stockholders_Equity_Details_4

7. Stockholders' Equity (Details - Warrant activity) (Warrant, USD $)	9 Months Ended	12 Months Ended
	Sep. 30, 2014	Dec. 31, 2013
Warrant	'	'
Number of warrants	'	'
Warrants outstanding, beginning balance	346,400	'
Warrants granted	'	346,400
Warrants exercisable	346,400	'
Warrants outstanding, ending balance	346,400	346,400
Weighted average exercise price	'	'
Warrants outstanding average exercise price, beginning price	$3.22	'
Warrants granted	'	$3.22
Warrants exercisable	$3.22	$3.22
Warrants outstanding average exercise price, ending price	$3.22	$3.22
Weighted average remaining contracted term	'	'
Warrants exercisable	'3 months 25 days	'6 months 26 days
Warrants outstanding	'3 months 25 days	'6 months 26 days
Weighted average grant date fair value	$0.25	'

7_Stockholders_Equity_Details_5

7. Stockholders' Equity (Details - warrant assumptions) (USD $)	9 Months Ended
	Sep. 30, 2014
Warrants issued total 46,400	'
Stock price	$0.01
Contractual term	'24 months
Expected volatility	29.13%
Risk free interest rate	0.15%
Dividend yield	0.00%
Warrants issued total 300,000	'
Stock price	$2.50
Contractual term	'2 years
Expected volatility	29.13%
Risk free interest rate	0.27%
Dividend yield	0.00%

7_Stockholders_Equity_Details_6

7. Stockholders' Equity (Details - EPS) (USD $)	3 Months Ended		9 Months Ended
	Sep. 30, 2014	Sep. 30, 2013	Sep. 30, 2014	Sep. 30, 2013
Basic:	'	'	'	'
Numerator - net income available to common stockholders	$2,339,607	$1,891,218	$7,718,514	$2,744,602
Denominator - weighted-average shares outstanding	30,281,386	29,692,110	30,186,893	29,610,287
Net income per share - Basic	$0.08	$0.06	$0.26	$0.09
Diluted:	'	'	'	'
Net income available to common stockholders	2,339,607	1,891,218	7,718,514	2,744,602
Interest expense on convertible debt, net of taxes	3,750	13,285	11,250	39,856
Diluted net income	$2,343,357	$1,904,503	$7,729,764	$2,784,458
Weighted-average shares outstanding	30,281,386	29,692,110	30,186,893	29,610,287
Weighted-average equivalent shares from convertible debt	222,222	322,222	222,222	245,706
Weighted-average equivalent shares from Series C convertible preferred stock	0	203,233	0	203,233
Weighted-average equivalent shares from Series D convertible preferred stock	200,000	0	143,590	0
Weighed-average equivalent shares from Series E convertible preferred stock	38,043	0	12,821	0
Diluted Shares Outstanding	30,741,651	30,217,565	30,565,526	30,059,226
Net income per share - Diluted	$0.08	$0.06	$0.25	$0.09

7_Stockholders_Equity_Details_7

7. Stockholders' Equity (Details - Antidilutive shares)	9 Months Ended
	Sep. 30, 2014	Sep. 30, 2013
Antidilutive securities	24,741,400	22,266,400
Stock Options [Member]	'	'
Antidilutive securities	24,395,000	23,170,000
Warrants [Member]	'	'
Antidilutive securities	346,400	346,400

8_Income_Taxes_Details_Income_

8. Income Taxes (Details - Income tax provision) (USD $)	9 Months Ended
	Sep. 30, 2014	Sep. 30, 2013
Current provision:	'	'
Federal	$5,300,405	$2,042,400
State	887,800	218,100
Deferred provision:	'	'
Federal	959,500	-546,300
State	102,600	-58,300
Total	$7,250,305	$1,655,900

8_Income_Taxes_Details_Effecti

8. Income Taxes (Details - Effective tax rate)	9 Months Ended
	Sep. 30, 2014	Sep. 30, 2013
Income Tax Disclosure [Abstract]	'	'
Expected federal income tax at 34% statutory rate	35.00%	34.00%
State income taxes	3.50%	3.60%
Permanent differences	0.10%	0.00%
Change in valuation allowance	0.00%	0.00%
Income tax provision (benefit)	38.60%	37.60%

8_Income_Taxes_Details_Deferre

8. Income Taxes (Details - Deferred tax assets) (USD $)	Sep. 30, 2014	Dec. 31, 2013
Deferred income tax assets:	'	'
Allowance for bad debts	$0	$1,362,900
Accrued compensation	686,700	385,700
Stock options	318,800	170,300
Total deferred income tax assets	1,005,500	1,918,900
Deferred income tax liabilities:	'	'
Property and equipment	-105,000	-76,100
Intangible amortization	-255,800	-136,000
Total deferred income tax liabilities	-360,800	-212,100
Net deferred income taxes:	'	'
Current	686,700	1,748,600
Non-current	-42,000	-41,800
Net deferred tax	$644,700	$1,706,800

9_Business_Combinations_Detail

9. Business Combinations (Details - Goodwill) (USD $)	Sep. 30, 2014	Dec. 31, 2013
Goodwill	$5,317,347	$1,425,999
Medical Billing Choices	'	'
Goodwill	1,202,112	1,202,112
PB Laboratories	'	'
Goodwill	107,124	107,124
Biohealth Medical Laboratory	'	'
Goodwill	116,763	116,763
Clinlab, Inc.	'	'
Goodwill	2,261,532	0
GlobalOne Information Technologies, LLC	'	'
Goodwill	176,816	0
Epinez Diagnostic Laboratories [Member]	'	'
Goodwill	$1,453,000	$0

9_Business_Combinations_Detail1

9. Business Combinations (Details - Acquisitions) (USD $)	9 Months Ended
	Sep. 30, 2014	Sep. 30, 2013	Dec. 31, 2013
Consideration Given	'	'	'
Cash	$1,600,000	$735,052	'
Fair value of identifiable assets acquired and liabilities assumed:	'	'	'
Goodwill and unidentified intangible assets	5,317,347	'	1,425,999
Epinez Diagnostic Laboratories [Member]	'	'	'
Consideration Given	'	'	'
Cash	100,000	'	'
Notes Payable	400,000	'	'
Series E Preferred Stock	800,000	'	'
Total consideration	1,300,000	'	'
Fair value of identifiable assets acquired and liabilities assumed:	'	'	'
Accounts receivable	80,000	'	'
Property and equipment	27,000	'	'
Accounts payable and accrued expenses	-260,000	'	'
Identifiable intangible assets	0	'	'
Total identifiable net assets	-153,000	'	'
Goodwill and unidentified intangible assets	1,453,000	'	0
Total consideration	1,300,000	'	'
GlobalOne Information Technologies, LLC	'	'	'
Consideration Given	'	'	'
Cash	500,000	'	'
Common stock	25,000	'	'
Contingent acquisition liability	150,000	'	'
Total consideration	675,000	'	'
Fair value of identifiable assets acquired and liabilities assumed:	'	'	'
Accounts receivable	93,270	'	'
Accounts payable and accrued expenses	-95,086	'	'
Software	500,000	'	'
Identifiable intangible assets	0	'	'
Total identifiable net assets	498,184	'	'
Goodwill and unidentified intangible assets	176,816	'	0
Total consideration	675,000	'	'
Clinlab, Inc.	'	'	'
Consideration Given	'	'	'
Cash	1,000,000	'	'
Series D Preferred stock	1,250,000	'	'
Contingent acquisition liability	54,017	'	'
Total consideration	2,304,017	'	'
Fair value of identifiable assets acquired and liabilities assumed:	'	'	'
Cash	31,671	'	'
Accounts receivable	54,017	'	'
Prepaid expenses	241	'	'
Security deposit	700	'	'
Accounts payable and accrued expenses	-44,144	'	'
Identifiable intangible assets	0	'	'
Total identifiable net assets	42,485	'	'
Goodwill and unidentified intangible assets	2,261,532	'	0
Total consideration	$2,304,017	'	'